Abstract: Disclosed are compounds that regulate REV-ERB nuclear receptors that would be useful for treatment of various diseases. These compounds may be used in therapeutic applications such as in the treatment of neurodegenerative disease such as anxiety disorder, autoimmune diseases or disorders, or muscular disorders such as sarcopenia.

Abstract: Disclosed are methods and compositions for determining immunodominant peptides of target enzymes used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are immunodominant peptides for N-acetylgalactosamine-6-sulfatase (GALNS). Also disclosed are methods of inducing oral tolerance towards a target enzyme through oral administration of immunodominant peptides prior to commencing enzyme replacement therapy. More specifically disclosed is a method of inducing oral tolerance for GALNS, by orally administering specific immunodominant peptides for GALNS; in subjects suffering from mucopolysaccharidosis type IVA prior to commencing enzyme replacement therapy using GALNS.

Abstract: In one aspect, the present disclosure describes new estrogen receptor-related orphan receptor (EER) inverse agonist compounds. Also described are pharmaceutical formulations, methods of synthesis and uses thereof.

Abstract: The present disclosure is directed to modified hepatitis virus C (HCV) E2 glycoprotein antigens and their use for treating, preventing or reducing the severity or likelihood of HCV infection.

Abstract: The present disclosure is directed to modified plant cells and plants having increased seed number and seed size. Studies identified genes such as ARF8, YDK1, RNA Pol IV, RNA Pol V, DCL3, AGO6, CMT3 and DRM2 as linked to seed characteristics and the inventors therefore propose modulating the expression and/or activity of these target genes in plants as an approach to increase/improve seed production.

Abstract: The present disclosure provides methods of preparing heterostructures of a carbon-based structure and a metal oxide structure. Also provided are heterostructures formed via the methods described herein and devices comprising such heterostructures.

Abstract: The present disclosure relates generally to tissue engineering. Disclosed herein are biomimetic sponges useful for tissue regeneration and methods for making biomimetic sponges.

Abstract: In some aspects, the present disclosure provides compounds of the formula: (I) or (II) wherein the variables are as defined herein. In some embodiments, these compounds may be used to treat cancer or other hyperproliferative diseases, as well as atherosclerosis and coronary artery disease.

Abstract: Disclosed herein are methods for treating neuropathic pain in a subject in need thereof. The methods include: administering to a subject in need thereof a therapeutically effective amount of an antagonist of P2Y14.

Abstract: This invention relates to a novel method of treating solid tumors of the head and neck. More specifically, the invention relates to the use of Momordicine-I (M-I), an extract of bitter melon (Momordica charantia), to treat solid tumors, particularly those of the head and neck as well as the breast. Methods and compositions are disclosed related to administrating Momordicine-I with lipophilic solvents to subjects in need.

Abstract: Disclosed are capped nanoparticles that are effectively trapped within an aqueous gelling solution to produce stable gels and function as a contrast agent for vascular imaging. The contrast agent has good radioopacity, is inexpensive to produce, and is safe to handle. This provides a new method to image the fine vasculature of biological systems.

Abstract: The present disclosure relates to catheters, and more particularly, to urinary catheters that can be used with an endoscope as well as a catheter system comprising a catheter and an endoscope, wherein the endoscope is disposed in the lumen of the catheter. In one instance, a catheter system includes an endoscope and a catheter. The endoscope has an insertion tube sized and shaped to be inserted into a body lumen of a patient. The catheter includes an elongate body having an axis and proximal and distal end portions space apart from one another along the axis. The elongate body is sized and shaped to be received in the body lumen. The elongate body defines a lumen extending between the proximal and distal end portions. The lumen is sized and shaped to receive the insertion tube of the endoscope.

Abstract: Among the various aspects of the present disclosure is the provision of a method of treating a neurodegenerative disease in a subject in need thereof comprising administering a therapeutically effective amount of a TAR DNA-binding protein (TDP-43) modulating agent comprising an RNA oligonucleotide.

Abstract: The present disclosure provides compositions and method targeting GPER for the treatment of cancers, such as breast cancers and leukemias, gallstone disease, and for conferring of neuroprotection on a subject. Also disclosed are high throughput assays for identifying antagonists of GPER.

Abstract: The present invention generally relates to various polycyclic aromatic selenoxide compounds, methods for preparing these compounds, and methods of us these and other compounds to generate ground state atomic oxygen.

Abstract: A two-factor authentication system includes a mobile device having a vibration element configured to generate a vibration sequence based on a unique vibration code received by the mobile device. A two-factor authentication server is communicatively coupled to the mobile device and is configured to send the unique vibration code to the mobile device in response to the two-factor authentication server receiving a two-factor authentication request. A vibration receiver is configured to support the mobile device and communicatively coupled to the two-factor authentication server. The vibration receiver includes a vibration sensor configured to detect the vibration sequence generated by the mobile device based on the unique vibration code and generate a vibration authentication signal based on the detected vibration sequence.

Abstract: Disclosed are methods and compositions for determining immunodominant peptides of target enzymes used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are immunodominant peptides for N-acetylgalactosamine-6-sulfatase (GALNS). Also disclosed are methods of inducing oral tolerance towards a target enzyme through oral administration of immunodominant peptides prior to commencing enzyme replacement therapy. More specifically disclosed is a method of inducing oral tolerance for GALNS, by orally administering specific immunodominant peptides for GALNS; in subjects suffering from mucopolysaccharidosis type IVA prior to commencing enzyme replacement therapy using GALNS.

Abstract: A telepathology system is associated with an edge network shared among participating users for remote control of a microscope. The microscope includes a camera operable to receive image data of a specimen. The telepathology system is capable of receiving image data from the microscope, pre-processing the image data at network edge, sending the pre-processed image digitally to the participating users via a web server on the edge network, and controlling the image data, via instructions from the participating users.

Abstract: The present disclosure provides inhibitors of microorganisms including viruses and fungi of the formula (I) or (II) wherein the variables are defined herein. Also provided are methods of treatment using these agents in the treatment of infections of microorganisms such as viruses and fungi.

Abstract: Provided herein are compounds of the formula: wherein the variables are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds may be used for the treatment of diseases or disorders, such as an infection of an antibiotic resistant bacteria.